Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is in the preclinical stage of development and intends to file for orphan drug designation prior to entering the clinical development pathway. Its legacy business consists of an proprietary library of patented bioactive peptides. Its lead drug development candidate, HB4208, is a polypeptide DNA deoxyribonucleic (DNA) damage response (DDR) enzyme for topical treatment of the rare genetic disorder (orphan disease) XP. Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. The company is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. The company is also engaged in the treatment of skin conditions.
Follow-Up Questions
Qui est le CEO de Helix BioMedix Inc ?
Ms. Robin Carmichael est le President de Helix BioMedix Inc, il a rejoint l'entreprise depuis 2007.
Quelle est la performance du prix de l'action HXBM ?
Le prix actuel de HXBM est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Helix BioMedix Inc ?
Helix BioMedix Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Helix BioMedix Inc ?
La capitalisation boursière actuelle de Helix BioMedix Inc est de $0
